Replies

Table 1 Baseline characteristic of the study population.

	Control (n = 15)	Ivermectin (n = 30)	P value
Age (year)	38•1 ± 11•7	42•3 ± 12•8	0•29
Gender
Female	5 (33%)	15 (50%)	0•29
Male	10 (67%)	15 (50%)
Weight (kg)	79•7 ± 14•4	75•3 ± 15•0	0•35
Overweight	8 (53%)	6 (20%)	0•05
Obesity I	2 (13%)	11 (37%)	0•20
Obesity II	1 (7%)	1 (3%)	0•79
Obesity III	1 (7%)	1 (3%)	0•79
Oxygen saturation <94%	0	1 (3%)	0•63
Log viral load (log10 copies/reaction)	5•39 ± 1•56 (n = 12)	4•18 ± 1•60 (n = 20)	0•05
Hematology
White blood cell count (cell/µL)	4857 ± 1874	6014 ± 2402	0•09
Lymphocyte count (cell/µL)	1478 ± 266	1744 ± 747	0•09
Biomarkers
Lactate dehydrogenase (IU/L)	460 ± 117	468 ± 140	0•85
Ferritin (mg/dL)	1318 ± 1969	1071 ± 1304	0•66
D-dimer (µg/mL)	1•5 (0•1–2•8)	1•5 (0•5–1•8)	0•82
Time from symptoms onset (day)	3•6 ± 1•4	3•5 ± 1•0	0•78
Body temperature ≥37•5 °C	1 (7%)	4 (13%)	0•70
WHO-ordinal scale
3	13 (87%)	29 (97%)	0•20
4	2 (13%)	1 (3%)
Ground glass opacities in thoracic imaging	6 (40%)	14 (47%)	0•67
Comorbidities
Hypertension	3 (20%)	3 (10%)	0•35
Diabetes	1 (7%)	6 (20%)	0•24
Chronic lung disease/Asthma	1 (7%)	4 (13%)	0•50

Numeric variables are reported as median (IQR) or mean ± standard deviation• Categoric variables are reported as counts (%). Overweight: Body mass index (BMI) 25–29•9 kg/m2; Obesity I: BMI 30–34•9 kg/m2; Obesity II: BMI 35–39•9 kg/m2; Obesity III: BMI >40 kg/m2.

Fig. 2 Viral load by quantitative RT-PCR on upper respiratory tract secretions since baseline in patients receiving IVM 0•6 mg/kg/day for 5 days versus untreated controls.
Fig. 3: Viral load reduction between baseline and day-5 (median and IQR) in untreated controls and IVM treated patients discriminated by their median IVM plasma concentrations
Fig. 4 Viral load decay rates by quantitative RT-PCR on upper respiratory tract secretions in untreated controls and IVM treated patients according to median plasma concentrations of IVM. Data are expressed as median (IQR)

re: log viral load 5•39 ± 1•56 (n = 12) - vs - 4•18 ± 1•60 (n = 20)

is this before or after trials? and were all trial participants alive at day 30 post-first-symptoms? were any rehospitalized since Sept 2020?

At the end of the study the viral load was reduced, but it doesn’t say cleared. Does this mean, as we’ve seen in Brazil, that temporarily reducing but not clearing a viral load, then reexposure, leads to mutations? (similar to the process leading to superbugs)?

Fig. 2 Viral load by quantitative RT-PCR on upper respiratory tract secretions since baseline in patients receiving IVM 0•6 mg/kg/day for 5 days versus untreated controls.

Fig. 3: Viral load reduction between baseline and day-5 (median and IQR) in untreated controls and IVM treated patients discriminated by their median IVM plasma concentrations

Fig. 4 Viral load decay rates by quantitative RT-PCR on upper respiratory tract secretions in untreated controls and IVM treated patients according to median plasma concentrations of IVM. Data are expressed as median (IQR)